Chong Kun Dang Pharmaceutical Corp - Product Pipeline Review - 2016

Published: Dec, 2016 | Pages: 63 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Chong Kun Dang Pharmaceutical Corp - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'Chong Kun Dang Pharmaceutical Corp - Product Pipeline Review - 2016', provides an overview of the Chong Kun Dang Pharmaceutical Corp's pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Chong Kun Dang Pharmaceutical Corp, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Chong Kun Dang Pharmaceutical Corp
- The report provides overview of Chong Kun Dang Pharmaceutical Corp including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Chong Kun Dang Pharmaceutical Corp's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Chong Kun Dang Pharmaceutical Corp's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate Chong Kun Dang Pharmaceutical Corp's strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Chong Kun Dang Pharmaceutical Corp
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Chong Kun Dang Pharmaceutical Corp's pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Chong Kun Dang Pharmaceutical Corp Snapshot 6
Chong Kun Dang Pharmaceutical Corp Overview 6
Key Facts 6
Chong Kun Dang Pharmaceutical Corp - Research and Development Overview 7
Key Therapeutic Areas 7
Chong Kun Dang Pharmaceutical Corp - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Combination Treatment Modalities 12
Chong Kun Dang Pharmaceutical Corp - Pipeline Products Glance 13
Chong Kun Dang Pharmaceutical Corp - Late Stage Pipeline Products 13
Phase III Products/Combination Treatment Modalities 13
Chong Kun Dang Pharmaceutical Corp - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
Chong Kun Dang Pharmaceutical Corp - Early Stage Pipeline Products 16
Preclinical Products/Combination Treatment Modalities 16
Chong Kun Dang Pharmaceutical Corp - Drug Profiles 17
(amlodipine besylate + candesartan cilexetil) - Drug Profile 17
Product Description 17
Mechanism Of Action 17
R&D Progress 17
(atorvastatin calcium + choline fenofibrate) - Drug Profile 19
Product Description 19
Mechanism Of Action 19
R&D Progress 19
(atorvastatin calcium + ezetimibe) - Drug Profile 20
Product Description 20
Mechanism Of Action 20
R&D Progress 20
(lobeglitazone + metformin hydrochloride XR) - Drug Profile 21
Product Description 21
Mechanism Of Action 21
R&D Progress 21
(tadalafil + tamsulosin hydrochloride) - Drug Profile 22
Product Description 22
Mechanism Of Action 22
R&D Progress 22
CKD-390 - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
CKD-504 - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
CKD-506 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
CKD-516 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
CKD-519 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
CKD-581 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
CKD-L - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
darbepoetin alfa - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
difelikefalin - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
hyaluronate sodium - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
leuprolide acetate SR - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
levocabastine hydrochloride + mometasone furoate - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
LT-1001 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
nepodin - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
pegfilgrastim - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
pregabalin SR - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
ranibizumab biosimilar - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
tamsulosin hydrochloride SR - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
Vaccine to Target IFN-Alpha for Chronic Viral Infections, Dermatomyositis and Systemic Lupus Erythematosus - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Chong Kun Dang Pharmaceutical Corp - Pipeline Analysis 52
Chong Kun Dang Pharmaceutical Corp - Pipeline Products by Target 52
Chong Kun Dang Pharmaceutical Corp - Pipeline Products by Route of Administration 54
Chong Kun Dang Pharmaceutical Corp - Pipeline Products by Molecule Type 55
Chong Kun Dang Pharmaceutical Corp - Pipeline Products by Mechanism of Action 56
Chong Kun Dang Pharmaceutical Corp - Dormant Projects 58
Chong Kun Dang Pharmaceutical Corp - Discontinued Pipeline Products 59
Discontinued Pipeline Product Profiles 59
beloranib 59
Chong Kun Dang Pharmaceutical Corp - Company Statement 60
Chong Kun Dang Pharmaceutical Corp - Locations And Subsidiaries 61
Head Office 61
Other Locations & Subsidiaries 61
Appendix 62
Methodology 62
Coverage 62
Secondary Research 62
Primary Research 62
Expert Panel Validation 62
Contact Us 62
Disclaimer 63

List of Tables

Chong Kun Dang Pharmaceutical Corp, Key Facts 6
Chong Kun Dang Pharmaceutical Corp - Pipeline by Indication, 2016 8
Chong Kun Dang Pharmaceutical Corp - Pipeline by Stage of Development, 2016 10
Chong Kun Dang Pharmaceutical Corp - Monotherapy Products in Pipeline, 2016 11
Chong Kun Dang Pharmaceutical Corp - Combination Treatment Modalities in Pipeline, 2016 12
Chong Kun Dang Pharmaceutical Corp - Phase III, 2016 13
Chong Kun Dang Pharmaceutical Corp - Phase II, 2016 14
Chong Kun Dang Pharmaceutical Corp - Phase I, 2016 15
Chong Kun Dang Pharmaceutical Corp - Preclinical, 2016 16
Chong Kun Dang Pharmaceutical Corp - Pipeline by Target, 2016 53
Chong Kun Dang Pharmaceutical Corp - Pipeline by Route of Administration, 2016 54
Chong Kun Dang Pharmaceutical Corp - Pipeline by Molecule Type, 2016 55
Chong Kun Dang Pharmaceutical Corp - Pipeline Products by Mechanism of Action, 2016 57
Chong Kun Dang Pharmaceutical Corp - Dormant Developmental Projects,2016 58
Chong Kun Dang Pharmaceutical Corp - Discontinued Pipeline Products, 2016 59
Chong Kun Dang Pharmaceutical Corp, Other Locations 61